Literature DB >> 19391158

Retinal deimination in aging and disease.

Sanjoy K Bhattacharya1.   

Abstract

Deimination is a posttranslational modification and refers to the conversion of protein bound arginine into citrulline. In the retina, deimination is predominantly catalyzed by Peptidylarginine deiminase type 2 (PAD2). PAD2 expression and deimination are found in many different retinal layers: choroid, retinal pigment epithelium (RPE), photoreceptors, inner plexiform layer, inner nuclear layer, and retinal ganglion cell (RGC) layer. Although decreased retinal deimination and PAD2 expression have been found during normal aging, elevated PAD2 expression and deimination have been observed in age-related neurodegenerative diseases. The role of deimination in normal physiology and in late-onset and progressive ocular or retinal degenerative diseases, such as glaucoma and experimental autoimmune encephalomyelitis remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19391158     DOI: 10.1002/iub.184

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  17 in total

1.  Proteomics analyses of human optic nerve head astrocytes following biomechanical strain.

Authors:  Ronan S Rogers; Moyez Dharsee; Suzanne Ackloo; Jeremy M Sivak; John G Flanagan
Journal:  Mol Cell Proteomics       Date:  2011-11-29       Impact factor: 5.911

2.  Synthesis and screening of a haloacetamidine containing library to identify PAD4 selective inhibitors.

Authors:  Justin E Jones; Jessica L Slack; Pengfei Fang; Xuesen Zhang; Venkataraman Subramanian; Corey P Causey; Scott A Coonrod; Min Guo; Paul R Thompson
Journal:  ACS Chem Biol       Date:  2011-10-21       Impact factor: 5.100

3.  The role of deimination in ATP5b mRNA transport in a transgenic mouse model of multiple sclerosis.

Authors:  Di Ding; Mabel Enriquez-Algeciras; Kunjan R Dave; Miguel Perez-Pinzon; Sanjoy K Bhattacharya
Journal:  EMBO Rep       Date:  2012-03-01       Impact factor: 8.807

4.  Aberrant glycosylation in the human trabecular meshwork.

Authors:  Adam E Sienkiewicz; Brandon N Rosenberg; Genea Edwards; Teresia A Carreon; Sanjoy K Bhattacharya
Journal:  Proteomics Clin Appl       Date:  2014-03-07       Impact factor: 3.494

Review 5.  An interplay of structure and intrinsic disorder in the functionality of peptidylarginine deiminases, a family of key autoimmunity-related enzymes.

Authors:  Mohammed Alghamdi; Khaled A Al Ghamdi; Rizwan H Khan; Vladimir N Uversky; Elrashdy M Redwan
Journal:  Cell Mol Life Sci       Date:  2019-07-24       Impact factor: 9.261

6.  The Role of Deimination in Regenerative Reprogramming of Neurons.

Authors:  Di Ding; Mabel Enriquez-Algeciras; Anddre Osmar Valdivia; Juan Torres; Cameron Pole; John W Thompson; Tsung-Han Chou; Miguel Perez-Pinzon; Vittorio Porciatti; Susan Udin; Eric Nestler; Sanjoy K Bhattacharya
Journal:  Mol Neurobiol       Date:  2018-07-26       Impact factor: 5.590

Review 7.  Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential.

Authors:  Justin E Jones; Corey P Causey; Bryan Knuckley; Jessica L Slack-Noyes; Paul R Thompson
Journal:  Curr Opin Drug Discov Devel       Date:  2009-09

Review 8.  The immune response in glaucoma: a perspective on the roles of oxidative stress.

Authors:  Gülgün Tezel
Journal:  Exp Eye Res       Date:  2010-08-13       Impact factor: 3.467

9.  Deimination restores inner retinal visual function in murine demyelinating disease.

Authors:  Mabel Enriquez-Algeciras; Di Ding; Fabrizio G Mastronardi; Robert E Marc; Vittorio Porciatti; Sanjoy K Bhattacharya
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

10.  Retinal deimination and PAD2 levels in retinas from donors with age-related macular degeneration (AMD).

Authors:  Vera L Bonilha; Karen G Shadrach; Mary E Rayborn; Yong Li; Gayle J T Pauer; Stephanie A Hagstrom; Sanjoy K Bhattacharya; Joe G Hollyfield
Journal:  Exp Eye Res       Date:  2013-04-03       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.